A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis

Trial Profile

A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs BI 655064 (Primary)
  • Indications Lupus nephritis; Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 18 Apr 2017 Planned End Date changed from 1 May 2019 to 22 Oct 2019.
    • 18 Apr 2017 Planned primary completion date changed from 1 Mar 2019 to 28 Aug 2019.
    • 14 Feb 2017 Planned End Date changed from 1 Nov 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top